AAAdnan Ali

Adnan Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adnan Ali has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In reply:

    by Adnan Ali, Russell L. Gruen, Biswadev Mitra

  • Open Access

    Tranexamic Acid Timing and Mortality Impact After Trauma

    by Adnan Ali, Russell L. Gruen, Stephen A. Bernard, Brian Burns, Andrew B. Forbes, Dashiell C. Gantner, Colin J. McArthur, Marc Maegele, Biswadev Mitra


  • Open Access

    Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

    by Nicholas D. James, Noel W. Clarke, Adrian Cook, Adnan Ali, Alex P. Hoyle, Gerhardt Attard, Christopher D. Brawley, Simon Chowdhury, William R. Cross, David P. Dearnaley, et al.

    Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy for prostate cancer. This long‐term analysis in metastatic patients was planned for 3 years after the first results. Standard‐of‐care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC‐alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly‐diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow‐up, 329 SOC‐alone deaths (118 low‐risk, 178 high‐risk) and 244 SOC + AAP deaths (75 low‐risk, 145 high‐risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50‐0.71; P = 0.31 × 10−9) favoured SOC + AAP, with 5‐years survival improved from 41% SOC‐alone to 60% SOC + AAP. This was similar in low‐risk (HR = 0.55; 95% CI: 0.41‐0.76) and high‐risk (HR = 0.54; 95% CI: 0.43‐0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.


  • Open Access

    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer

    by A. Cannistraci, P. Hascoet, A. Ali, P. Mundra, N. W. Clarke, V. Pavet, R. Marais

    Prostate cancer (PCa) is the fifth leading cause of cancer related deaths worldwide, in part due to a lack of molecular stratification tools that can distinguish primary tumours that will remain indolent from those that will metastasise. Amongst potential molecular biomarkers, microRNAs (miRs) have attracted particular interest because of their high stability in body fluids and fixed tissues. These small non-coding RNAs modulate several physiological and pathological processes, including cancer progression. Herein we explore the prognostic potential and the functional role of miRs in localised PCa and their relation to nodal metastasis. We define a 7-miR signature that is associated with poor survival independently of age, Gleason score, pathological T state, N stage and surgical margin status and that is also prognostic for disease-free survival in patients with intermediate-risk localised disease. Within our 7-miR signature, we show that miR-378a-3p (hereafter miR-378a) levels are low in primary tumours compared to benign prostate tissue, and also lower in Gleason score 8–9 compared to Gleason 6–7 PCa. We demonstrate that miR-378a impairs glucose metabolism and reduces proliferation in PCa cells through independent mechanisms, and we identify glucose transporter 1 (GLUT1) messenger RNA as a direct target of miR-378a. We show that GLUT1 inhibition hampers glycolysis, leading to cell death. Our data provides a rational for a new PCa stratification strategy based on miR expression, and it reveals that miR-378a and GLUT1 are potential therapeutic targets in highly aggressive glycolytic PCa.


  • Open Access

    The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”

    by Adnan Ali, Alex P. Hoyle, Christopher C. Parker, Christopher D. Brawley, Adrian Cook, Claire Amos, Joanna Calvert, Hassan Douis, Malcolm D. Mason, Gerhardt Attard, et al.


  • Top Cited Papers
    Open Access

    Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

    by N.W. Clarke, A. Ali, F.C. Ingleby, A. Hoyle, C.L. Amos, G. Attard, C.D. Brawley, J. Calvert, S. Chowdhury, A. Cook, et al.

    STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.


  • Importance of non‐regional lymph nodes in assigning risk in primary metastatic prostate cancer

    by Adnan Ali, Alexander Hoyle, Hitesh Mistry, Noel W. Clarke

    Objective: To determine the prognostic relevance of non‐regional lymph node ( NRLN ) metastases presenting synchronously with bone metastases in metastatic prostate cancer ( mPC a) for guiding treatment decisions based on oligometastatic definitions. Patients and Methods: Patients diagnosed with mPC a between 2004 and 2013 were identified from the Surveillance, Epidemiology and End Results database and were grouped by metastatic sites into only NRLN , only bone, bone + NRLN and other sites ± bone/ NRLN metastases. Multivariate Cox and competing risk regression analyses were performed to compare the risks of all‐cause mortality ( ACM ) and prostate cancer‐specific mortality ( PCSM ) associated with bone + NRLN metastases before and after propensity‐score matching to patients with only bone metastases. This was complemented with landmark and supplementary analyses. Results: Of 17 167 patients with mPC a identified, 63.1% presented with only bone metastases, while bone and NRLN metastases co‐occurred in 8.9% of the cohort. On multivariate analyses, after adjusting for potential confounders (clinical and sociodemographic), patients with bone + NRLN metastases had a significantly higher risk of ACM (hazard ratio [ HR ] 1.161, 95% confidence interval [ CI ] 1.084–1.243; P < 0.001) and PCSM (subdistribution HR 1.149, 95% CI 1.067–1.237; P < 0.001) compared with patients with only bone metastases. Landmark analyses limited to survivors of ≥6 and ≥12 months again showed a significantly increased risk of ACM for patients presenting with bone + NRLN metastases compared with patients with only bone metastases. In a subsequent 1:1 propensity‐score‐matched cohort of patients with bone + NRLN metastases and only bone metastases, the bone + NRLN group had higher multivariate‐adjusted hazard rates for ACM ( HR 1.202, 95% CI 1.102–1.311; P < 0.001) and PCSM (subdistribution HR 1.146, 95% CI 1.044–1.259; P = 0.004). Conclusions: Patients with concomitant NRLN and bone metastases have a higher risk of death, NRLN and bone metastases therefore representing a high‐risk feature, when compared with patients with bone metastases alone. The current therapeutic stratification of ‘low‐’ vs ‘high‐volume’ disease does not account for this phenomenon, and patients requiring aggressive combination therapy may not receive maximum therapeutic benefit as a consequence.